Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to position…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukemia patient populations covering 171 countries…

Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…